Abiopharma

🔍 Jones Leslie Shane (Executive)

Company: NATURES SUNSHINE PRODUCTS INC (NATR)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 4,004 shares of Common Shares (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 105,020.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,756 shares of Common Shares at $25.915 per share (Direct)
  Date: 2026-05-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 103,264.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,484 shares of Common Shares (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 105,748.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 1,090 shares of Common Shares at $25.915 per share (Direct)
  Date: 2026-05-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 104,658.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These shares are vested shares resulting from the company's achievement of an adjusted EBITDA milestone of $51.1M over a rolling 12-month period pursuant to an April 20, 2023, performance-based restricted stock unit grant to the reporting person. As a result, half of the target vests upon achievement of the target and another half will vest one year following the achievement of such milestone.
• F2: Represents shares of NATR common stock withheld to pay taxes upon vesting of restricted stock units granted to the reporting person on May 5, 2026. The number of shares withheld was determined on May 5, 2026, based on the closing price of NATR common stock on that date.
• F3: These shares are vested shares resulting from the company's achievement of an adjusted EBITDA milestone of $52M over a rolling 12-month period pursuant to a March 10, 2025, performance-based restricted stock unit grant to the reporting person. As a result, half of the target vests upon achievement of the target and another half will vest one year following the achievement of such milestone.